In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $100.00. The company's shares closed last Tuesday at $90.48. According to TipRanks.com, Goldstein is a 1-star analyst with an average return of -0.6% and a 34.0% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals. Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $98.20, implying an 8.9% upside from current levels.
https://www.tipranks.com/news/blurbs/mizuho-securities-maintains-their-buy-rating-on-merck-company-mrk?utm_source=advfn.com&utm_medium=referral
Merck (NYSE:MRK)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Merck Charts.